信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

已收盘 05-07 16:08:11

91.100

+0.500

+0.55%

最高93.800	最低89.950	成交量1,481万
今开91.500	昨收90.600	日振幅4.25%
总市值1,581亿	流通市值1,581亿	总股本17.35亿
成交额13.53亿	换手率0.85%	流通股本17.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":91.1,"timestamp":1778141291004,"preClose":90.6,"halted":0,"volume":14809689,"delay":0,"changeRate":0.005518763796909493,"floatShares":1735000000,"shares":1735000000,"eps":0.5413868733288953,"marketStatus":"已收盘","change":0.5,"latestTime":"05-07 16:08:11","open":91.5,"high":93.8,"low":89.95,"amount":1353497025,"amplitude":0.042494,"askPrice":91.15,"askSize":103000,"bidPrice":91.1,"bidSize":141500,"shortable":3,"etf":0,"ttmEps":0.5413868733288953,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778203800000},"marketStatusCode":5,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":90.6,"openAndCloseTimeList":[[1778117400000,1778126400000],[1778130000000,1778140800000]],"volumeRatio":1.27638,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.3118,"impliedVolPercentile":0.0526},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"1126071478","title":"信达生物2026年4月股份变动月报表，新增3,046,194股","url":"https://stock-news.laohu8.com/highlight/detail?id=1126071478","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126071478?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:00","pubTimestamp":1778144457,"startTime":"0","endTime":"0","summary":"信达生物制药于2026年5月7日发布2026年4月股份变动月报表，报告期截至2026年4月30日。在已发行股份方面，截至2026年3月底，公司普通股已发行股本为1,735,191,039股；本月新增3,046,194股后，于2026年4月底的普通股已发行总数增至1,738,237,233股。同时，依据2020年受限制股份计划，公司新增发行2,780,786股普通股。上述股份期权行使为公司带来共计HKD 9,273,229资金。报告期内并无购回或注销股票事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632093124","title":"高盛：上调信达生物(01801)目标价至105.94港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2632093124","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632093124?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:31","pubTimestamp":1777887092,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，上调信达生物2026至2028年每股盈利预测，分别为1.42元、3.11元、4.19元人民币，以反映首季销售胜预期;目标价由104.61港元微升至105.94港元;评级“买入”。今年首季产品收入超过38亿元人民币，同比增逾50%，高于该行预测的约35亿元人民币。强劲增长主要受玛仕度肽等产品组合扩张，以及新纳入国家医保目录的产品所带动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632982009","title":"中金：维持信达生物(01801)“跑赢行业”评级 目标价118.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632982009","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632982009?lang=zh_cn&edition=full","pubTime":"2026-05-04 11:12","pubTimestamp":1777864349,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持信达生物“跑赢行业”评级，基于DCF模型，维持目标价118.3港币不变，较当前股价有31.4%的上行空间。近日，公司预告将在2026 ASCO会议公布IBI363在免疫耐药及一线非小细胞肺癌的概念验证数据，以及多项信迪利单抗临床数据。该行建议关注ASCO数据读出情况，及关注后续IBI363和武田合作的全球注册临床进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126049752","title":"异动解读 | 信达生物盘中大涨5.18%，一季度产品收入同比增超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126049752","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126049752?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:36","pubTimestamp":1777516587,"startTime":"0","endTime":"0","summary":"信达生物今日盘中大涨5.18%，引起了市场的广泛关注。消息面上，公司公布了2026年第一季度的强劲业绩。数据显示，公司产品收入录得超过38亿元人民币，同比增长超过50%。这一增长印证了公司“双轮驱动”策略的成功执行，增强了市场对其高成长性和确定性的信心。具体来看，公司肿瘤领域的领先地位日益显著，五款酪氨酸激酶抑制剂新增纳入国家医保药品目录后实现快速放量。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631338572","title":"港股异动 | 信达生物(01801)涨超5% 一季度产品收入同比增超五成 正在推进三项高价值潜力分子","url":"https://stock-news.laohu8.com/highlight/detail?id=2631338572","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631338572?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:00","pubTimestamp":1777514400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物涨超5%，截至发稿，涨5.18%，报89.25港元，成交额3.25亿港元。消息面上，4月30日，信达生物发布公告，于2026年第一季度，公司产品收入录得超过人民币38亿元，同比增长超过50%，此强劲势头印证了公司“双轮驱动”策略的成功执行。公司肿瘤领域的领先地位日益显著，五款酪氨酸激酶抑制剂新增纳入国家医保药品目录后实现快速放量。公告称，信达生物持续推进全球化创新，为公司价值打开持续向上的成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU2328871848.SGD","VXUS","BK1583","LU2242644610.SGD","HK0000165453.HKD","LU2097828557.USD","BK1161","LU2488822045.USD","LU0455707207.USD","BK4585","LU2097828474.EUR","LU0502904849.HKD","LU2097828631.EUR","LU2097828714.EUR","01801","BK1589","LU2097828805.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631755645","title":"信达生物(01801)一季度产品收入超38亿元 同比增长超过50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631755645","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631755645?lang=zh_cn&edition=full","pubTime":"2026-04-30 07:57","pubTimestamp":1777507021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，于2026年第一季度，公司产品收入录得超过人民币38亿元，同比增长超过50%，此强劲势头印证了公司“双轮驱动”策略的成功执行。2026年第一季度的强劲表现增强了公司收入持续快速增长的信心，进一步巩固公司作为中国领先生物制药公司的高成长性及确定性。展望未来，公司国内业务规模的持续稳固扩张及全球创新管线的加速推进，将稳步推动公司实现“成为国际一流的生物制药公司”的长期愿景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"信达生物(01801)一季度产品收入超38亿元 同比增长超过50%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0455707207.USD","LU2488822045.USD","BK1583","LU0502904849.HKD","HK0000165453.HKD","LU2097828631.EUR","LU2097828714.EUR","BK1161","LU2097828557.USD","LU2097828805.USD","LU2242644610.SGD","BK1589","LU2328871848.SGD","LU2097828474.EUR","01801","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119046471","title":"信达生物：2025年营收与盈利双升，“肿瘤+综合品线”驱动全球化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1119046471","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119046471?lang=zh_cn&edition=full","pubTime":"2026-04-28 23:05","pubTimestamp":1777388737,"startTime":"0","endTime":"0","summary":"信达生物于2025年实现收入人民币130.42亿元，同比上升38.4%，其中医药产品销售收入达人民币118.96亿元，增长44.6%。受益于收入规模快速扩大及产能效率提升，公司在报告期内成功扭亏为盈，实现IFRS净利润人民币8.14亿元，而上年度仍处于亏损。展望后续发展，公司将继续深耕“肿瘤+综合品线”双轮驱动战略，加大国际化投入并拓展新一代免疫治疗、心血管及代谢病创新药物的全球临床研究，进一步提升研发与商业化效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物：2025年营收与盈利双升，“肿瘤+综合品线”驱动全球化布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630244273","title":"美银证券：信达生物(01801)2月销售额同比增长32% 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2630244273","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630244273?lang=zh_cn&edition=full","pubTime":"2026-04-28 14:06","pubTimestamp":1777356397,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，维持信达生物“买入”评级，目标价为116.8港元。信达生物2月样本药品总销售额同比增长32%至4.873亿元人民币。其中贝伐珠单抗销售额同比增长31.7%至1.505亿元人民币;信迪利单抗销售额则轻微同比下降2.7%至1.814亿元人民币。其他产品方面，利妥昔单抗、托莱西单抗注射液销售额分别为5,780万/5,020万元人民币，同比增长12.3%/1,766.9%。玛仕度肽月销售额为820万元，环比增长5.1%，是少数在假期期间仍能维持销售的产品之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629892154","title":"港股信达生物午后一度涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629892154","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629892154?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:47","pubTimestamp":1777009667,"startTime":"0","endTime":"0","summary":"4月24日，信达生物(01801.HK)午后一度涨超4%，截至发稿，涨3.73%，报86.1港元，成交额6.25亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243717852255.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243717852255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828714.EUR","LU2328871848.SGD","LU2097828631.EUR","LU0502904849.HKD","LU2242644610.SGD","LU2097828805.USD","LU1969619763.USD","BK4588","LU2488822045.USD","01801","BK1161","LU2097828557.USD","BK4585","LU2097828474.EUR","BK1589","LU0455707207.USD","HK0000165453.HKD","VXUS","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629892564","title":"港股异动 | 信达生物(01801)午后涨超4% 达伯乐®关键研究长期随访数据于AACR年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2629892564","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629892564?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:41","pubTimestamp":1777009279,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物午后涨超4%，截至发稿，涨3.73%，报86.1港元，成交额6.25亿港元。消息面上，据信达生物官微消息，近日，新一代ROS1酪氨酸激酶抑制剂达伯乐关键研究长期随访数据在2026美国癌症研究协会年会上以口头报告和壁报形式发布。达伯乐是一种口服、强效、具有中枢神经系统活性、高选择性的新一代ROS1抑制剂。目前，经过NMPA及FDA优先审评和突破性疗法认定，他雷替尼已在中国大陆、中国澳门、美国、日本等多地获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1583","HK0000165453.HKD","LU2328871848.SGD","LU2097828631.EUR","BK4585","LU2097828474.EUR","LU2097828557.USD","BK1589","LU2242644610.SGD","01801","LU2097828805.USD","LU2097828714.EUR","LU0455707207.USD","LU1969619763.USD","BK4588","BK1161","LU0502904849.HKD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","02637","BK1589","159992","LU2097828805.USD","BK1574","LU2328871848.SGD","06990","BK1161","BK1191","LU0196878994.USD","LU2488822045.USD","01801","LU2097828631.EUR","LU2097828474.EUR","06855","LU2242644610.SGD","HK0000165453.HKD","BK1583","BK1515","LU2097828714.EUR","09969","LU0502904849.HKD","01672","01477","LU2097828557.USD","LU1969619763.USD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["DIG","GUSH","159992","LU2097828714.EUR","BWET","DBC","BK1583","01530","DRIP","BK1593","OILU","UGA","BK4570","01801","DRLL","06978","LU2097828631.EUR","OIH","LU2328871848.SGD","03692","HK0000165453.HKD","LU2488822045.USD","USE","OILT","BNO","LU0455707207.USD","BK1191","OILK","BK1574","BK1161","LU2097828557.USD","LU2097828805.USD","09995","DBO","IXC","LU0502904849.HKD","DBE","DUG","BK4585","ERX","VDE","USL","LU1969619763.USD","USOI","BK1589","LU2097828474.EUR","IEO","PXJ","VXUS","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109281848","title":"异动解读 | 信达生物盘中大跌6.12%，因出现大手卖出交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1109281848","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109281848?lang=zh_cn&edition=full","pubTime":"2026-04-23 12:03","pubTimestamp":1776917014,"startTime":"0","endTime":"0","summary":"信达生物今日盘中股价出现大幅下跌，跌幅达到6.12%，引起了市场关注。消息面上，该股在交易时段内出现一笔大手卖出交易，成交量为10.55万股，成交价为83.5港元，涉及金额约880.925万港元。此类大额卖出行为通常会给股价带来即时下行压力，可能是导致本次盘中下跌的直接原因之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629102069","title":"广发基金刘杰旗下港股创新药ETF广发一季报最新持仓，重仓信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629102069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629102069?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:14","pubTimestamp":1776813242,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日广发基金旗下刘杰管理的广发中证香港创新药交易型开放式指数基金(QDII)公布一季报，近1年净值增长率53.44%。并对信达生物增仓154.0万股，为该基金第一大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200013499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["513120","BK1583","LU2097828474.EUR","LU2097828631.EUR","LU2328871848.SGD","LU2488822045.USD","LU0502904849.HKD","LU2097828557.USD","01801","LU2097828714.EUR","LU2242644610.SGD","LU2097828805.USD","BK1589","HK0000165453.HKD","BK1161","LU1969619763.USD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629696490","title":"博时基金万琼旗下博时恒生医疗保健ETF一季报最新持仓，重仓信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629696490","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629696490?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:13","pubTimestamp":1776813233,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日博时基金旗下万琼管理的博时恒生医疗保健交易型开放式指数基金(QDII)公布一季报，近1年净值增长率35.82%。并对信达生物增仓11.9万股，为该基金第一大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200013493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2097828474.EUR","BK1161","LU2097828714.EUR","159506","LU0502904849.HKD","LU2488822045.USD","BK1589","LU2097828631.EUR","LU2097828557.USD","BK1583","LU2328871848.SGD","LU2242644610.SGD","HK0000165453.HKD","01801","LU0455707207.USD","LU1969619763.USD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629696770","title":"华夏基金赵宗庭旗下华夏恒生香港上市生物科技ETF一季报最新持仓，重仓信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629696770","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629696770?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:12","pubTimestamp":1776813141,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日华夏基金旗下赵宗庭管理的华夏恒生生物科技交易型开放式指数基金(QDII)公布一季报，近1年净值增长率42.91%。并对信达生物增仓95.1万股，为该基金第一大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200013429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2488822045.USD","LU2328871848.SGD","LU2097828631.EUR","LU2097828557.USD","LU2097828805.USD","01801","LU2097828714.EUR","BK1589","LU1969619763.USD","BK1583","LU0455707207.USD","LU0502904849.HKD","LU2097828474.EUR","HK0000165453.HKD","LU2242644610.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629037923","title":"兴证全球基金谢治宇旗下兴全合宜A一季报最新持仓，重仓信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629037923","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629037923?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:57","pubTimestamp":1776779848,"startTime":"0","endTime":"0","summary":"证券之星消息，4月21日兴证全球基金旗下谢治宇 薛怡然管理的兴全合宜灵活配置混合型基金(LOF)公布一季报，近1年净值增长率48.59%。与上一季度相比，该基金前十大重仓股新增贝壳-W，华海清科，阿里巴巴-W，德业股份；其中信达生物持仓占比6.96%，为该基金第一大重仓股；佰维存储，汇量科技，澜起科技，药明生物等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100052514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2097828557.USD","BK1161","LU2097828714.EUR","HK0000165453.HKD","163417","LU2097828474.EUR","LU0455707207.USD","LU2097828631.EUR","BK1583","LU0502904849.HKD","LU2097828805.USD","01801","LU2328871848.SGD","LU2488822045.USD","BK1589","LU1969619763.USD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629037318","title":"谢治宇一季度最新持仓披露！加码化工与储能","url":"https://stock-news.laohu8.com/highlight/detail?id=2629037318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629037318?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:31","pubTimestamp":1776778295,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月21日，知名基金经理谢治宇管理的基金公布了一季报。以兴全合润为例，谢治宇在一季度进行了明确的行业切换。此外，晶晨股份亦获得小幅增持。减持方面，中际旭创持仓数量由约344万股缩减至约213万股，减持幅度显著。基金一季度对海外算力、半导体设备、储能以及化工板块进行了重点配置，部分化工龙头经历了格局的重塑与分化后将重新走向上升通道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999006514.SGD","LU2476274720.SGD","HBBD.SI","688008","300750","LU0979878070.USD","002008","605117","LU1979443071.USD","LU2213484517.USD","LU2097829019.USD","SG9999001689.USD","LU0345776255.USD","BK1097","02423","LU1880383366.USD","LU2097828805.USD","LU0169518387.USD","000683","688099","600160","688120","BK0229","LU0359201885.HKD","LU2580892789.USD","89988","BK1618","IE0032431581.USD","BABA","ALBmain","LU0531971595.HKD","LU0572940350.SGD","EVS.SI","LU1720050803.USD","LU0561508036.HKD","LU0192582467.USD","SG9999001903.USD","LU1102505762.USD","LU0588545490.SGD","03750","LU1993786604.SGD","LU0456842615.SGD","01801","09969","LU0231483743.USD","300308","600426","09988","LU0456827905.SGD","LU0348783662.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628719049","title":"招银国际：医疗板块风险偏好有温和的修复 推荐翰森制药(03692)等6股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628719049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628719049?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:36","pubTimestamp":1776656176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨12.3%，跑赢MSCI中国指数13.6%。近期在中国政府工作报告将生物医学列为新兴支柱产业的政策催化下，板块风险偏好有温和的修复。同时，AI制药技术突破与中国创新药出海 BD 的爆发形成双重共振，该行预期产业基本面加速向好。招商国际给予该6只股份“买入”的投资评级，目标价分别为46.41港元、113.86港元、34.87港元、10.34港元、82港元及35.46美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1191","159891","LU2097828714.EUR","LU2328871848.SGD","LU2097828631.EUR","LU0502904849.HKD","01530","LU2242644610.SGD","LU2097828805.USD","BK1141","LU1969619763.USD","02268","BK1574","LU2488822045.USD","01801","01167","BK1161","SG9999014674.SGD","LU2097828557.USD","LU2097828474.EUR","BK1589","LU0455707207.USD","HK0000165453.HKD","03692","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627113702","title":"下一个“减肥药”？降脂针从 2000 元变 300 元，药企疯狂内卷会否重蹈覆辙","url":"https://stock-news.laohu8.com/highlight/detail?id=2627113702","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627113702?lang=zh_cn&edition=full","pubTime":"2026-04-16 21:49","pubTimestamp":1776347370,"startTime":"0","endTime":"0","summary":"单针从9988元骤降至2790元，近2000元的降脂针“腰斩再腰斩”至300元级！长效降脂针医保落地至今早已满三个月，这场颠覆性的价格变革，让曾经的“天价救命针”变身“亲民药”，诺华、安进、信达生物等中外药企争相入局，咨询量、备货量迎来爆发式激增，千亿美元降脂赛道瞬间沸腾，一场没有硝烟的市场洗牌正激烈上演。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604163707833565.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604163707833565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","LU0502904849.HKD","HK0000165453.HKD","LU2097828557.USD","LU2097828805.USD","LU2488822045.USD","LU1969619763.USD","BK1161","LU2097828714.EUR","LU2097828631.EUR","BK1583","LU2242644610.SGD","LU2328871848.SGD","01801","LU0455707207.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0671},{"period":"1month","weight":-0.0098},{"period":"3month","weight":0.1339},{"period":"6month","weight":0.0634},{"period":"1year","weight":0.6685},{"period":"ytd","weight":0.1882}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0437},{"period":"3month","weight":-0.025},{"period":"6month","weight":-0.0011},{"period":"1year","weight":0.1567},{"period":"ytd","weight":0.0228}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.5,"avgChangeRate":0.024806},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}